The Filings Report

Bio-Techne Corp.

TECHNasdaqCIK 842023Healthcare / Biotechnologyfiscal year ends June69 quarters since 2009

Revenue, Q4 FY2026
$321M
+1.3% on Q4 FY2025
Net income
$55M
+408.2% on Q4 FY2025
Free cash flow
$87M
−6.8% on Q4 FY2025
Diluted EPS
—
not filed for a derived quarter
Revenue, TTM
$1.2B
trailing four quarters
Net margin, TTM
15.0%
net income $182M
Free cash flow, TTM
$263M
$292M less $29M capex
Cash and equivalents
$265M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+0.8%
157M shares, Jun 30, 2026
Buybacks, TTM
$42M
0.4% of market value
Dividends, TTM
$50M
0.4% of market value
Market value
$11.4B
at the close, buybacks

Latest quarter Q4 FY2026, filed August 24, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q4 FY2026, the quarter ended June 30, 2026, Bio-Techne Corp. reported revenue of $321M, +1.3% on Q4 FY2025, and net income of $55M (+408.2%). Operating margin was 23.1%. Free cash flow, operating cash flow less capital expenditures, was $87M ($95M less $8M). The income statement for this quarter is derived from the annual filing, so no per-share figure is shown; per-share values are never computed by subtraction.

The last 16 quarters

Q1 FY2023 to Q4 FY2026, through the filing of August 24, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200M$300M$400MQ1'23, Revenue: $270MQ1'23, Net income: $90MQ1'23Q2'23, Revenue: $272MQ2'23, Net income: $50MQ2'23Q3'23, Revenue: $294MQ3'23, Net income: $70MQ3'23Q4'23, Revenue: $301MQ4'23, Net income: $75MQ4'23Q1'24, Revenue: $277MQ1'24, Net income: $51MQ1'24Q2'24, Revenue: $273MQ2'24, Net income: $27MQ2'24Q3'24, Revenue: $303MQ3'24, Net income: $49MQ3'24Q4'24, Revenue: $306MQ4'24, Net income: $41MQ4'24Q1'25, Revenue: $289MQ1'25, Net income: $34MQ1'25Q2'25, Revenue: $297MQ2'25, Net income: $35MQ2'25Q3'25, Revenue: $316MQ3'25, Net income: $23MQ3'25Q4'25, Revenue: $317MQ4'25, Net income: −$18MQ4'25Q1'26, Revenue: $287MQ1'26, Net income: $38MQ1'26Q2'26, Revenue: $296MQ2'26, Net income: $38MQ2'26Q3'26, Revenue: $311MQ3'26, Net income: $51MQ3'26Q4'26, Revenue: $321MQ4'26, Net income: $55MQ4'26−$100M$0$100M$200M$300M$400MQ1'23, Revenue: $270MQ1'23, Net income: $90MQ2'23, Revenue: $272MQ2'23, Net income: $50MQ2'23Q3'23, Revenue: $294MQ3'23, Net income: $70MQ4'23, Revenue: $301MQ4'23, Net income: $75MQ4'23Q1'24, Revenue: $277MQ1'24, Net income: $51MQ2'24, Revenue: $273MQ2'24, Net income: $27MQ2'24Q3'24, Revenue: $303MQ3'24, Net income: $49MQ4'24, Revenue: $306MQ4'24, Net income: $41MQ4'24Q1'25, Revenue: $289MQ1'25, Net income: $34MQ2'25, Revenue: $297MQ2'25, Net income: $35MQ2'25Q3'25, Revenue: $316MQ3'25, Net income: $23MQ4'25, Revenue: $317MQ4'25, Net income: −$18MQ4'25Q1'26, Revenue: $287MQ1'26, Net income: $38MQ2'26, Revenue: $296MQ2'26, Net income: $38MQ2'26Q3'26, Revenue: $311MQ3'26, Net income: $51MQ4'26, Revenue: $321MQ4'26, Net income: $55MQ4'26

Net income losses drawn in red.

Free cash flow
$0$25M$50M$75M$100MQ1'23, Free cash flow: $47MQ1'23Q2'23, Free cash flow: $58MQ2'23Q3'23, Free cash flow: $39MQ3'23Q4'23, Free cash flow: $73MQ4'23Q1'24, Free cash flow: $46MQ1'24Q2'24, Free cash flow: $68MQ2'24Q3'24, Free cash flow: $65MQ3'24Q4'24, Free cash flow: $58MQ4'24Q1'25, Free cash flow: $55MQ1'25Q2'25, Free cash flow: $78MQ2'25Q3'25, Free cash flow: $31MQ3'25Q4'25, Free cash flow: $93MQ4'25Q1'26, Free cash flow: $22MQ1'26Q2'26, Free cash flow: $76MQ2'26Q3'26, Free cash flow: $78MQ3'26Q4'26, Free cash flow: $87MQ4'26$0$25M$50M$75M$100MQ1'23, Free cash flow: $47MQ2'23, Free cash flow: $58MQ2'23Q3'23, Free cash flow: $39MQ4'23, Free cash flow: $73MQ4'23Q1'24, Free cash flow: $46MQ2'24, Free cash flow: $68MQ2'24Q3'24, Free cash flow: $65MQ4'24, Free cash flow: $58MQ4'24Q1'25, Free cash flow: $55MQ2'25, Free cash flow: $78MQ2'25Q3'25, Free cash flow: $31MQ4'25, Free cash flow: $93MQ4'25Q1'26, Free cash flow: $22MQ2'26, Free cash flow: $76MQ2'26Q3'26, Free cash flow: $78MQ4'26, Free cash flow: $87MQ4'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300MQ1'23, Cash and equivalents: $165MQ1'23Q2'23, Cash and equivalents: $165MQ2'23Q3'23, Cash and equivalents: $127MQ3'23Q4'23, Cash and equivalents: $181MQ4'23Q1'24, Cash and equivalents: $149MQ1'24Q2'24, Cash and equivalents: $130MQ2'24Q3'24, Cash and equivalents: $140MQ3'24Q4'24, Cash and equivalents: $152MQ4'24Q1'25, Cash and equivalents: $188MQ1'25Q2'25, Cash and equivalents: $178MQ2'25Q3'25, Cash and equivalents: $141MQ3'25Q4'25, Cash and equivalents: $162MQ4'25Q1'26, Cash and equivalents: $145MQ1'26Q2'26, Cash and equivalents: $173MQ2'26Q3'26, Cash and equivalents: $210MQ3'26Q4'26, Cash and equivalents: $265MQ4'26$0$100M$200M$300MQ1'23, Cash and equivalents: $165MQ2'23, Cash and equivalents: $165MQ2'23Q3'23, Cash and equivalents: $127MQ4'23, Cash and equivalents: $181MQ4'23Q1'24, Cash and equivalents: $149MQ2'24, Cash and equivalents: $130MQ2'24Q3'24, Cash and equivalents: $140MQ4'24, Cash and equivalents: $152MQ4'24Q1'25, Cash and equivalents: $188MQ2'25, Cash and equivalents: $178MQ2'25Q3'25, Cash and equivalents: $141MQ4'25, Cash and equivalents: $162MQ4'25Q1'26, Cash and equivalents: $145MQ2'26, Cash and equivalents: $173MQ2'26Q3'26, Cash and equivalents: $210MQ4'26, Cash and equivalents: $265MQ4'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q4 FY2026 filed August 24, 2026.

Bio-Techne Corp. income statement, quarterly
Millions of dollarsQ4 FY2026ended Jun 30, 2026filed Aug 24, 2026Q3 FY2026ended Mar 31, 2026filed May 6, 2026Q2 FY2026ended Dec 31, 2025filed Feb 4, 2026Q1 FY2026ended Sep 30, 2025filed Nov 5, 2025Q4 FY2025ended Jun 30, 2025filed Aug 22, 2025Q3 FY2025ended Mar 31, 2025filed May 8, 2025Q2 FY2025ended Dec 31, 2024filed Feb 6, 2025Q1 FY2025ended Sep 30, 2024filed Nov 5, 2024YoYQ4 FY2026vs Q4 FY2025
Revenue321311296287317316297289+1.3%
Cost of revenue11010310598118102103106−7.1%
Gross profit211208191188199215194183+6.3%
Research and development—————————
Selling, general and administrative113109114116197151121119−42.4%
Operating income74755448(24)394740+411.3%
Other income (expense)(4)(4)(4)010(5)0−459.2%
Pretax income71715148(23)384340+409.2%
Income tax16201310(5)1687+410.0%
Net income55513838(18)233534+408.2%
Diluted EPS ($)—0.320.240.24—0.140.220.21—
Diluted shares (millions)—157157156—159161161—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q4 FY2026 filed August 24, 2026.

Bio-Techne Corp. balance sheet, quarterly
Millions of dollarsQ4 FY2026ended Jun 30, 2026filed Aug 24, 2026Q3 FY2026ended Mar 31, 2026filed May 6, 2026Q2 FY2026ended Dec 31, 2025filed Feb 4, 2026Q1 FY2026ended Sep 30, 2025filed Nov 5, 2025Q4 FY2025ended Jun 30, 2025filed Aug 22, 2025Q3 FY2025ended Mar 31, 2025filed May 8, 2025Q2 FY2025ended Dec 31, 2024filed Feb 6, 2025Q1 FY2025ended Sep 30, 2024filed Nov 5, 2024YoYQ4 FY2026vs Q4 FY2025
Cash and equivalents265210173145162141178188+63.2%
Short-term investments—————00——
Total current assets744688637610608627635649+22.4%
Total assets2,5872,5512,5232,5262,5582,6442,6702,736+1.1%
Total current liabilities164153140145176169161142−6.9%
Long-term debt—————————
Total liabilities—————————
Stockholders’ equity2,1082,0852,011—1,9192,0182,0782,139+9.9%
Shares outstanding (millions)157157156156156157158159—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q4 FY2026 filed August 24, 2026.

Bio-Techne Corp. cash flow statement, quarterly
Millions of dollarsQ4 FY2026ended Jun 30, 2026filed Aug 24, 2026Q3 FY2026ended Mar 31, 2026filed May 6, 2026Q2 FY2026ended Dec 31, 2025filed Feb 4, 2026Q1 FY2026ended Sep 30, 2025filed Nov 5, 2025Q4 FY2025ended Jun 30, 2025filed Aug 22, 2025Q3 FY2025ended Mar 31, 2025filed May 8, 2025Q2 FY2025ended Dec 31, 2024filed Feb 6, 2025Q1 FY2025ended Sep 30, 2024filed Nov 5, 2024YoYQ4 FY2026vs Q4 FY2025
Operating cash flow9587822898418464−2.8%
Capital expenditures896551079+73.4%
Free cash flow (CFO − capex)8778762293317855−6.8%
Depreciation and amortization2424252427282728−11.0%
Share repurchases42000100100——−58.4%
Dividends paid1213121212131313+0.8%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2026 filed August 24, 2026.

Income statement

Bio-Techne Corp. income statement, annual
Millions of dollarsFY2026ended Jun 30, 2026filed Aug 24, 2026FY2025ended Jun 30, 2025filed Aug 22, 2025FY2024ended Jun 30, 2024filed Aug 22, 2024FY2023ended Jun 30, 2023filed Aug 23, 2023FY2022ended Jun 30, 2022filed Aug 24, 2022FY2021ended Jun 30, 2021filed Aug 25, 2021FY2020ended Jun 30, 2020filed Aug 26, 2020FY2019ended Jun 30, 2019filed Aug 28, 2019FY2018ended Jun 30, 2018filed Aug 27, 2018FY2017ended Jun 30, 2017filed Sep 7, 2017FY2016ended Jun 30, 2016filed Aug 29, 2016FY2015ended Jun 30, 2015filed Aug 31, 2015FY2014ended Jun 30, 2014filed Aug 29, 2014FY2013ended Jun 30, 2013filed Aug 29, 2013FY2012ended Jun 30, 2012filed Aug 29, 2012FY2011ended Jun 30, 2011filed Aug 29, 2011FY2010ended Jun 30, 2010filed Nov 9, 2010FY2009ended Jun 30, 2009filed Nov 9, 2010
Revenue1,2151,2201,1591,1371,106931739714643563499452358311315290269264
Cost of revenue4164293893673492982552412111881621451067979655556
Gross profit799790770770756633483473432375337307251231236225214208
Research and development——————————————————
Selling, general and administrative452589466378373325261264241200141119614342363334
Operating income2521022072992972371571471361211511471600166163156151
Other income (expense)(11)(4)(21)405(89)119(35)(10)(9)(3)722(4)205
Pretax income24198186339301148276112126112147154161161162165156—
Income tax5925185338947160364346504850534750
Net income182731682852721402299612676104108111113112112110105
Diluted EPS ($)1.160.461.051.761.660.871.46*0.62*0.83*0.51*0.70*0.72*0.75*0.76*0.76*0.76*0.73*0.69*
Diluted shares (millions)157160161162164162158*156*152*150*149*149*148*148*148*149*149*152*

Balance sheet

Bio-Techne Corp. balance sheet, annual
Millions of dollarsFY2026ended Jun 30, 2026filed Aug 24, 2026FY2025ended Jun 30, 2025filed Aug 22, 2025FY2024ended Jun 30, 2024filed Aug 22, 2024FY2023ended Jun 30, 2023filed Aug 23, 2023FY2022ended Jun 30, 2022filed Aug 24, 2022FY2021ended Jun 30, 2021filed Aug 25, 2021FY2020ended Jun 30, 2020filed Aug 26, 2020FY2019ended Jun 30, 2019filed Aug 28, 2019FY2018ended Jun 30, 2018filed Aug 27, 2018FY2017ended Jun 30, 2017filed Sep 7, 2017FY2016ended Jun 30, 2016filed Aug 29, 2016FY2015ended Jun 30, 2015filed Aug 31, 2015FY2014ended Jun 30, 2014filed Aug 29, 2014FY2013ended Jun 30, 2013filed Aug 29, 2013FY2012ended Jun 30, 2012filed Aug 29, 2012FY2011ended Jun 30, 2011filed Aug 29, 2011FY2010ended Jun 30, 2010filed Nov 9, 2010FY2009ended Jun 30, 2009filed Nov 9, 2010
Cash and equivalents2651621521811731991471011229264553191641177894161
Short-term investments——1247432—————————6345—
Total current assets744608617621606511521413398348254248469410347230201—
Total assets2,5872,5582,7042,6392,2952,2632,0281,8841,5931,5581,1301,063862778719618519472
Total current liabilities1641761591291761521071028013654402632361817—
Long-term debt——————————————————
Total liabilities——————————————————
Stockholders’ equity2,1081,9192,0691,9671,7021,5631,3811,1661,079950879847795738674586502456
Shares outstanding (millions)157156159158157*156*154*152*151*150*149*149*148*147*147*148*——

Cash flow statement

Bio-Techne Corp. cash flow statement, annual
Millions of dollarsFY2026ended Jun 30, 2026filed Aug 24, 2026FY2025ended Jun 30, 2025filed Aug 22, 2025FY2024ended Jun 30, 2024filed Aug 22, 2024FY2023ended Jun 30, 2023filed Aug 23, 2023FY2022ended Jun 30, 2022filed Aug 24, 2022FY2021ended Jun 30, 2021filed Aug 25, 2021FY2020ended Jun 30, 2020filed Aug 26, 2020FY2019ended Jun 30, 2019filed Aug 28, 2019FY2018ended Jun 30, 2018filed Aug 27, 2018FY2017ended Jun 30, 2017filed Sep 7, 2017FY2016ended Jun 30, 2016filed Aug 29, 2016FY2015ended Jun 30, 2015filed Aug 31, 2015FY2014ended Jun 30, 2014filed Aug 29, 2014FY2013ended Jun 30, 2013filed Aug 29, 2013FY2012ended Jun 30, 2012filed Aug 29, 2012FY2011ended Jun 30, 2011filed Aug 29, 2011FY2010ended Jun 30, 2010filed Nov 9, 2010FY2009ended Jun 30, 2009filed Nov 9, 2010
Operating cash flow292288299254325352205182170144144——124127127111111
Capital expenditures29316338454452252115172014226457
Free cash flow (CFO − capex)263257236216280308153156149129127——101121124107105
Depreciation and amortization9711011210710188837864604337191212988
Share repurchases4227680201614350150——0022421591
Dividends paid505050505050494848474847454341403828

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$437K
2 sales by 1 insider; officers and directors $437K

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 1, 2026Kelderman KimChief Executive Officer, Directortax withholding2,385$72.66$173K80,509Nov 3, 2026
Nov 1, 2026Hippel JamesCFOoption exercise11,545$0.00—181,816Nov 3, 2026
Nov 1, 2026Hippel JamesCFOtax withholding5,096$72.66$370K176,720Nov 3, 2026
Oct 29, 2026Vessey RupertDirectoraward2,750$0.00—13,737Nov 2, 2026
Oct 29, 2026Seth AlpnaDirectoraward2,750$0.00—18,161Nov 2, 2026
Oct 29, 2026Klimovsky Judith V.Directoraward2,750$0.00—6,532Nov 2, 2026
Oct 29, 2026Herr Amy E.Directoraward2,750$0.00—5,430Nov 2, 2026
Oct 29, 2026Keegan Joseph DDirectoraward2,750$0.00—18,161Nov 2, 2026
Oct 29, 2026Higgins John LDirectoraward2,750$0.00—80,004Nov 2, 2026
Oct 29, 2026Bushman Julie LDirectoraward2,750$0.00—11,525Nov 2, 2026
Oct 29, 2026Baumgartner Robert VDirectoraward2,750$0.00—59,634Nov 2, 2026
Sep 28, 2026Higgins John LDirectoroption exercise15,940$0.00—82,816Sep 30, 2026
Sep 28, 2026Higgins John LDirectortax withholding5,562$72.51$403K77,254Sep 30, 2026
Sep 22, 2026Baumgartner Robert VDirectoroption exercise15,940$0.00—62,443Sep 24, 2026
Sep 22, 2026Baumgartner Robert VDirectortax withholding5,559$72.55$403K56,884Sep 24, 2026
Aug 15, 2026Hippel JamesCFOoption exercise9,980$0.00—174,694Nov 2, 2026
Aug 15, 2026Hippel JamesCFOtax withholding4,423$72.40$320K170,271Nov 2, 2026
Aug 15, 2026Geist WilliamPRESIDENT, PROTEIN SCIENCESoption exercise6,547$0.00—27,050Nov 2, 2026
Aug 15, 2026Geist WilliamPRESIDENT, PROTEIN SCIENCEStax withholding2,019$72.40$146K25,031Nov 2, 2026
Aug 15, 2026Kelderman KimChief Executive Officer, Directoroption exercise21,736$0.00—93,849Nov 2, 2026
Aug 15, 2026Kelderman KimChief Executive Officer, Directortax withholding10,955$72.40$793K82,894Nov 2, 2026
Aug 15, 2026Bohnen ShaneSVP - General Counseloption exercise4,420$0.00—11,773Nov 2, 2026
Aug 15, 2026Bohnen ShaneSVP - General Counseltax withholding1,366$72.40$99K10,407Nov 2, 2026
Aug 15, 2026Kelderman KimChief Executive Officer, Directoroption exercise21,470$0.00—93,583Aug 18, 2026
Aug 15, 2026Kelderman KimChief Executive Officer, Directortax withholding10,821$72.40$783K82,762Aug 18, 2026

Full insider history for Bio-Techne Corp., or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held TECH in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded TECH by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$127K1,8000.00%trimmed −99.7%

Sources

Fiscal year ends in month 6; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BIO-TECHNE CORP, CIK 842023 on EDGAR
Extract generated
November 4, 2026
Withheld
none
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: operating income FY2013, other income FY2018
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss, NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/TECH.json